Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002912 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00002912: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00002912 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002912, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining PSC-833 with chemotherapy may reduce resistance to the drug and allow more cancer cells to be killed.
Interventions
- DRUG etoposide
- DRUG mitoxantrone hydrochloride
- DRUG valspodar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 1997-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002912
The ClinicalTrials.gov registry entry for NCT00002912 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which etoposide is the first listed.
NCT00002912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002912 about?
NCT00002912 is a clinical study titled "Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia". Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chem...
What is the current status of trial NCT00002912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 1997-01.
What interventions are being tested in trial NCT00002912?
The interventions under investigation include: etoposide (DRUG), mitoxantrone hydrochloride (DRUG), valspodar (DRUG).
Who is sponsoring clinical trial NCT00002912?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.